Primidone

Primidone

SCHEMBL3175374

CCC(C)C1(CC)C(=O)NC(=O)NC1=O.CCC1(c2ccccc2)C(=O)NCNC1=O

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A

The experimentally established mechanism targets of Primidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRB3 known ✓ P28472 1/20 0.44
GABRA2 known ✓ P47869 1/20 0.44
GABRB2 known ✓ P47870 1/20 0.44
POLB P06746 2/20 0.68
KMT2A Q03164 2/20 0.68
MEN1 O00255 1/20 0.68
CYP1A2 P05177 1/20 0.68
TSHR P16473 1/20 0.68
APEX1 P27695 1/20 0.68
TDP1 Q9NUW8 1/20 0.68
MMP2 P08253 5/20 0.50
MMP9 P14780 5/20 0.50
MMP3 P08254 3/20 0.50
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP3A4 P08684 1/20 0.44
OPRD1 P41143 1/20 0.44
LMNA P02545 4/20 0.41
MMP13 P45452 2/20 0.38
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenobarbital SCHEMBL1171829 0.85 KMT2A (0.87) POLBKMT2AMEN1CYP1A2TSHR
Primidone SCHEMBL34221 0.82 KMT2A (1.00) POLBKMT2AMEN1CYP1A2TSHR
Phenytoin SCHEMBL8662692 0.76 KMT2A (0.75) POLBKMT2AMEN1CYP1A2TSHR
Phenobarbital SCHEMBL19991483 0.76 MMP2 (0.75) POLBKMT2AMEN1CYP1A2TSHR
Phenobarbital SCHEMBL28099657 0.76 MMP2 (0.80) POLBKMT2AMEN1CYP1A2TSHR
Phenobarbital SCHEMBL16583 0.76 MMP2 (0.80) POLBKMT2AMEN1CYP1A2TSHR
Phenobarbital SCHEMBL18825042 0.76 MMP2 (0.80) POLBKMT2AMEN1CYP1A2TSHR
Phenobarbital SCHEMBL2592325 0.76 MMP2 (0.80) POLBKMT2AMEN1CYP1A2TSHR
Butabarbital SCHEMBL79255 0.76 CYP3A4 (0.71) POLBMMP2MMP9MMP3KDM4E
Butabarbital SCHEMBL79254 0.76 CYP3A4 (0.71) POLBMMP2MMP9MMP3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100021519-A1 Compositions and Methods for Treating or Preventing Diseases of Body Passageways SHENOY NARMADA 2010-01-28 US disclosed
EP-2019649-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS Shenoy, Narmada R. (US) 2009-02-04 EP disclosed
WO-2007127488-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS SHENOY NARMADA R (US) 2007-11-08 WO disclosed
US-20060121088-A1 Compositions and methods for treating or preventing diseases of body passageways ANGIOTECH INTERNATIONAL AG (CH) 2006-06-08 US disclosed
EP-1616563-A2 Perivascular administration of anti-angiogenic factors for treating or preventing vascular diseases Angiotech Pharmaceuticals, Inc. (CA) 2006-01-18 EP disclosed
EP-0914102-B8 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS ANGIOTECH PHARM INC (CA) 2005-11-02 EP disclosed
US-20050192235-A1 Compositions and methods for treating or preventing diseases of body passageways ANGIOTECH INTERNATIONAL AG 2005-09-01 US disclosed
US-20050137148-A1 Compositions and methods for treating or preventing diseases of body passageways ANGIOTECH INTERNATIONAL AG 2005-06-23 US disclosed
US-20050129736-A1 Compositions and methods for treating or preventing diseases of body passageways ANGIOTECH INTERNATIONAL AG 2005-06-16 US disclosed
US-20050107291-A1 Compositions and methods for treating or preventing diseases of body passageways ANGIOTECH INTERNATIONAL AG 2005-05-19 US disclosed
US-20050101635-A1 Compositions and methods for treating or preventing diseases of body passageways ANGIOTECH INTERNATIONAL AG 2005-05-12 US disclosed
US-20050096388-A1 Compositions and methods for treating or preventing diseases of body passageways ANGIOTECH INTERNATIONAL AG 2005-05-05 US disclosed
US-20040224023-A1 Compositions and methods for treating or preventing diseases of body passageways ANGIOTECH PHARMACEUTICALS, INC. (CA) 2004-11-11 US disclosed
US-6759431-B2 TREATING OR PREVENTING VASCULAR DISEASES ASSOCIATED WITH BODY PASSAGEWAYS, BY DELIVERING TO AN EXTERNAL PORTION OF THE BODY PASSAGEWAY A COMPOSITION COMPRISING PACLITAXEL, OR AN ANALOGUE OR DERIVATIVE THEREOF ANGIOTECH PHARMACEUTICALS, INC. (CA) 2004-07-06 US disclosed
US-20020052404-A1 Compositions and methods for treating or preventing diseases of body passageways ANGIOTECH PHARMACEUTICALS, INC. (CA) 2002-05-02 US disclosed
EP-0914102-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS Angiotech Pharmaceuticals, Inc. (CA) 1999-05-12 EP disclosed
WO-1997045105-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS ANGIOTECH PHARMACEUTICALS, INC. (CA) 1997-12-04 WO disclosed